Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2023

Boiarsky D, Lydon C A, Chambers E S, Sholl L M, Nishino M, Skoulidis F, Heymach J V, Luo J, Awad M M, Janne P A, Van Allen E M, Barbie D A, Vokes N I

Abstract excerpt

BACKGROUND: Prior studies characterized the association of molecular alterations with treatment-specific outcomes in KRAS-mutant (KRASMUT) lung adenocarcinoma (LUAD). Less is known about the prognostic role of molecular alterations and their associations with metastatic disease. PATIENTS AND METHODS: We analyzed clinicogenomic data from 1817 patients with KRASMUT LUAD sequenced at the Dana-Farber Cancer Institute...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to DNA Helicases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Adenocarcinoma of Lung

Share to Kelch-Like ECH-Associated Protein 1

Share to NF-E2-Related Factor 2

Share to Nuclear Proteins

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 37121400
DOI: 10.1016/j.annonc.2023.04.514
PMCID: PMC10425882

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.PMID 37121400Read ↗

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.Semantic proximity Read ↗

KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.Semantic proximity Read ↗

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.Semantic proximity Read ↗

Identification of Subsets of Genetic Alterations in KRAS-mutant Lung Cancer using Association Rule MiningSemantic proximity Read ↗

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.Semantic proximity Read ↗

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.Semantic proximity Read ↗

Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma.Semantic proximity Read ↗

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Semantic proximity Read ↗

Distinct molecular subtypes of KRASG12C-mutant lung adenocarcinoma: Insights into clinical outcomes, tumour microenvironments and therapeutic strategies.Semantic proximity Read ↗

Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining.Semantic proximity Read ↗

Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients.Semantic proximity Read ↗

Implication of Biomarker Mutations for Predicting Survival in Patients With Metastatic Lung Cancer to the Spine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.